レナリドマイドの世界市場レポート 2025年

レナリドマイド市場規模は、今後数年間で力強い成長が見込まれます。2029年には175億8,000万米ドルに成長し、CAGRは8.0%となります。予測期間における成長の背景には、適応拡大に対する規制当局の承認の増加、標的治療薬に対する需要の高まり、新興市場での採用、腫瘍研究開発への投資の増加、併用療法への治療パラダイムのシフト、費用対効果の高い治療選択肢を支持するヘルスケア政策の進化などがあります。予測期間における主な動向としては、新興市場での採用の増加、併用療法への注目の高まり、個別化医療アプローチへの需要の高まり、市場ダイナミクスに影響を与える規制の進展、治療決定における実臨床エビデンスの重視の高まり、血液悪性腫瘍以外の用途の拡大、市場競争力を形成する価格戦略の進化などが挙げられます。

予測される血液がん患者の増加は、レナリドマイド市場の拡大を促進します。血液細胞産生を阻害する異常細胞によって特徴づけられる血液がんは、高齢化、環境毒素、遺伝、ライフスタイルの変化などの要因に影響されます。レナリドマイドは、免疫システムを調整し、がん細胞の増殖を抑制し、悪性細胞の排除を促進することにより、血液がんの管理を支援します。例えば、米国がん協会のCancer Facts and Figures 2023レポートによると、2023年 1月に米国で新たに発生する骨髄腫の患者数は35,730人と推定され、その内訳は男性19,860人、女性15,870人です。さらに、米国では2023年に約18万4,720人が白血病、リンパ腫、骨髄腫と診断されると予測されており、レナリドマイド市場の成長をさらに後押ししています。

レナリドマイド市場の主なプレーヤーは、費用対効果の高い治療に対する需要の高まりに対応し、市場を拡大するため、レナリドマイドカプセルのジェネリック医薬品を含む革新的な医薬品の開発に注力しています。先発医薬品の効果を再現したレナリドマイドカプセルのジェネリック医薬品が人気を集めています。例えば、スイスの製薬会社サンドは2022年2月、欧州19カ国でレナリドマイドのジェネリック医薬品を発売しました。この薬は最新のESMOガイドラインに沿ったもので、多発性骨髄腫、濾胞性リンパ腫、骨髄異形成症候群関連貧血、再発または難治性のマントル細胞リンパ腫の患者にコスト削減の選択肢を提供します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界レナリドマイド PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のレナリドマイド市場：成長率分析
• 世界のレナリドマイド市場の実績：規模と成長, 2019-2024
• 世界のレナリドマイド市場の予測：規模と成長, 2024-2029, 2034F
• 世界レナリドマイド総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のレナリドマイド市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 5mgカプセル
• 10mgカプセル
• 15mgカプセル
• 25mgカプセル
• 世界のレナリドマイド市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 多発性骨髄腫（MM）
• 骨髄異形成症候群（MDS）
• リンパ腫
• その他の用途
• 世界のレナリドマイド市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• がん治療センター
• 調査機関

第7章 地域別・国別分析

• 世界のレナリドマイド市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のレナリドマイド市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• レナリドマイド市場：競合情勢
• レナリドマイド市場：企業プロファイル
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Amgen Inc Overview, Products and Services, Strategy and Financial Analysis
  • Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Sun Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Intas Pharmaceuticals Ltd
• Aurobindo Pharma
• Dr. Reddy's Laboratories
• Cipla Limited
• Apotex Inc
• Zydus Lifesciences Limited
• Alvogen
• Lotus Pharmaceutical
• Natco Pharma Limited
• Accord Healthcare
• Veranova
• Avra Laboratories Pvt. Ltd.
• Camber Pharmaceuticals Inc.
• Rochem International Inc
• Florencia Healthcare

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• レナリドマイド市場2029：新たな機会を提供する国
• レナリドマイド市場2029：新たな機会を提供するセグメント
• レナリドマイド市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Lenalidomide, classified as an immunomodulatory drug akin to thalidomide analogs, is chiefly employed in the treatment of multiple myeloma, a form of cancer impacting plasma cells, and in the management of select myelodysplastic syndromes (MDS). It works by modifying the immune system's response and impeding the proliferation and survival of cancerous cells.

Lenalidomide is available primarily in four dosage forms, 5mg, 10mg, 15mg, and 25mg capsules. The 5mg capsules contain 5 milligrams of the active ingredient and are utilized for multiple myeloma (MM), myelodysplastic syndromes (MDS), lymphoma, and other applications within hospitals, cancer treatment centers, and research institutions.

The lenalidomide market research report is one of a series of new reports from The Business Research Company that provides lenalidomide market statistics, including lenalidomide industry global market size, regional shares, competitors with lenalidomide market share, detailed lenalidomide market segments, market trends, and opportunities, and any further data you may need to thrive in the lenalidomide industry. This lenalidomide market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The lenalidomide market size has grown strongly in recent years. It will grow from $11.91 billion in 2024 to $12.91 billion in 2025 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to FDA approval for multiple myeloma, expansion into new geographic markets, introduction of generic versions, advancements in clinical research, strategic partnerships, increasing prevalence of blood cancers, and growing demand for cost-effective treatments.

The lenalidomide market size is expected to see strong growth in the next few years. It will grow to $17.58 billion in 2029 at a compound annual growth rate (CAGR) of 8.0%. The growth in the forecast period can be attributed to increased regulatory approvals for expanded indications, growing demand for targeted therapies, emerging market adoption, rising investments in oncology research and development, shifting treatment paradigms towards combination therapies, and evolving healthcare policies favoring cost-effective treatment options. Major trends in the forecast period include increased adoption in emerging markets, heightened focus on combination therapies, rising demand for personalized medicine approaches, regulatory advancements influencing market dynamics, growing emphasis on real-world evidence in treatment decisions, expanded applications beyond hematological malignancies, and evolving pricing strategies shaping market competitiveness.

The anticipated rise in blood cancer cases is set to drive the expansion of the lenalidomide market. Blood cancer, characterized by abnormal cells disrupting blood cell production, is influenced by factors such as aging populations, environmental toxins, genetics, and lifestyle changes. Lenalidomide aids in managing blood cancer by modulating the immune system, suppressing cancer cell growth, and facilitating the elimination of malignant cells. For instance, the Cancer Facts and Figures 2023 report from the American Cancer Society revealed an estimated 35,730 new myeloma cases in the US in January 2023, with 19,860 males and 15,870 females. Additionally, around 184,720 individuals in the United States are expected to be diagnosed with leukemia, lymphoma, or myeloma in 2023, further boosting the lenalidomide market growth.

Key players in the lenalidomide market are concentrating on developing innovative drugs, including generic versions of lenalidomide capsules, to cater to the rising demand for cost-effective treatments and broaden their market reach. Generic lenalidomide capsules, reproducing the original drug's effects, are gaining traction. For instance, in February 2022, Sandoz, a Swiss pharmaceutical company, introduced a generic lenalidomide version across 19 European countries. This medication, aligned with the latest ESMO guidelines, provides cost-saving options for patients with multiple myeloma, follicular lymphoma, myelodysplastic syndromes-related anemia, and relapsed or refractory mantle cell lymphoma.

In December 2023, Lotus Pharmaceutical, a US-based biopharmaceutical firm, formed a partnership with Fuji Pharma Co. Ltd. to distribute Lenalidomide capsules, a generic version of Revlimid, in the Japanese market. This collaboration leverages Fuji Pharma's expertise and market presence in producing and selling medical products.

Major companies operating in the lenalidomide market are Bristol-Myers Squibb Company, Novartis AG, Amgen Inc, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Intas Pharmaceuticals Ltd, Aurobindo Pharma, Dr. Reddy's Laboratories, Cipla Limited, Apotex Inc, Zydus Lifesciences Limited, Alvogen, Lotus Pharmaceutical, Natco Pharma Limited, Accord Healthcare, Veranova, Avra Laboratories Pvt. Ltd., Camber Pharmaceuticals Inc., Rochem International Inc, Florencia Healthcare, Alleviare Life Sciences Pvt Ltd., LGM Pharma LLC, Sarv Biolabs Pvt Ltd, Speciality Medicines Private Limited, Healthiza Lifescience Private Limited.

North America was the largest region in the lenalidomide market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lenalidomide market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the lenalidomide market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The lenalidomide market consists of sales of buccal patches, oral tablets, capsules, and powders. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Lenalidomide Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on lenalidomide market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for lenalidomide ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The lenalidomide market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: 5Mg Capsules; 10Mg Capsules; 15Mg Capsules; 25Mg Capsules
• 2) By Application: Multiple Myeloma (MM); Myelodysplastic Syndromes (MDS); Lymphoma; Other Applications
• 3) By End-User: Hospitals; Cancer Treatment Centers; Research Institutes
• Companies Mentioned: Bristol-Myers Squibb Company; Novartis AG; Amgen Inc; Teva Pharmaceutical Industries Ltd.; Sun Pharmaceutical Industries Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Lenalidomide Market Characteristics

3. Lenalidomide Market Trends And Strategies

4. Lenalidomide Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Lenalidomide Growth Analysis And Strategic Analysis Framework

• 5.1. Global Lenalidomide PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Lenalidomide Market Growth Rate Analysis
• 5.4. Global Lenalidomide Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Lenalidomide Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Lenalidomide Total Addressable Market (TAM)

6. Lenalidomide Market Segmentation

• 6.1. Global Lenalidomide Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 5Mg Capsules
• 10Mg Capsules
• 15Mg Capsules
• 25Mg Capsules
• 6.2. Global Lenalidomide Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Multiple Myeloma (MM)
• Myelodysplastic Syndromes (MDS)
• Lymphoma
• Other Applications
• 6.3. Global Lenalidomide Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Cancer Treatment Centers
• Research Institutes

7. Lenalidomide Market Regional And Country Analysis

• 7.1. Global Lenalidomide Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Lenalidomide Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Lenalidomide Market

• 8.1. Asia-Pacific Lenalidomide Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Lenalidomide Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Lenalidomide Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Lenalidomide Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Lenalidomide Market

• 9.1. China Lenalidomide Market Overview
• 9.2. China Lenalidomide Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Lenalidomide Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Lenalidomide Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Lenalidomide Market

• 10.1. India Lenalidomide Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Lenalidomide Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Lenalidomide Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Lenalidomide Market

• 11.1. Japan Lenalidomide Market Overview
• 11.2. Japan Lenalidomide Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Lenalidomide Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Lenalidomide Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Lenalidomide Market

• 12.1. Australia Lenalidomide Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Lenalidomide Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Lenalidomide Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Lenalidomide Market

• 13.1. Indonesia Lenalidomide Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Lenalidomide Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Lenalidomide Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Lenalidomide Market

• 14.1. South Korea Lenalidomide Market Overview
• 14.2. South Korea Lenalidomide Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Lenalidomide Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Lenalidomide Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Lenalidomide Market

• 15.1. Western Europe Lenalidomide Market Overview
• 15.2. Western Europe Lenalidomide Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Lenalidomide Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Lenalidomide Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Lenalidomide Market

• 16.1. UK Lenalidomide Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Lenalidomide Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Lenalidomide Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Lenalidomide Market

• 17.1. Germany Lenalidomide Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Lenalidomide Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Lenalidomide Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Lenalidomide Market

• 18.1. France Lenalidomide Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Lenalidomide Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Lenalidomide Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Lenalidomide Market

• 19.1. Italy Lenalidomide Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Lenalidomide Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Lenalidomide Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Lenalidomide Market

• 20.1. Spain Lenalidomide Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Lenalidomide Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Lenalidomide Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Lenalidomide Market

• 21.1. Eastern Europe Lenalidomide Market Overview
• 21.2. Eastern Europe Lenalidomide Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Lenalidomide Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Lenalidomide Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Lenalidomide Market

• 22.1. Russia Lenalidomide Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Lenalidomide Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Lenalidomide Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Lenalidomide Market

• 23.1. North America Lenalidomide Market Overview
• 23.2. North America Lenalidomide Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Lenalidomide Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Lenalidomide Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Lenalidomide Market

• 24.1. USA Lenalidomide Market Overview
• 24.2. USA Lenalidomide Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Lenalidomide Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Lenalidomide Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Lenalidomide Market

• 25.1. Canada Lenalidomide Market Overview
• 25.2. Canada Lenalidomide Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Lenalidomide Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Lenalidomide Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Lenalidomide Market

• 26.1. South America Lenalidomide Market Overview
• 26.2. South America Lenalidomide Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Lenalidomide Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Lenalidomide Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Lenalidomide Market

• 27.1. Brazil Lenalidomide Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Lenalidomide Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Lenalidomide Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Lenalidomide Market

• 28.1. Middle East Lenalidomide Market Overview
• 28.2. Middle East Lenalidomide Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Lenalidomide Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Lenalidomide Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Lenalidomide Market

• 29.1. Africa Lenalidomide Market Overview
• 29.2. Africa Lenalidomide Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Lenalidomide Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Lenalidomide Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Lenalidomide Market Competitive Landscape And Company Profiles

• 30.1. Lenalidomide Market Competitive Landscape
• 30.2. Lenalidomide Market Company Profiles
  • 30.2.1. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Amgen Inc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sun Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Lenalidomide Market Other Major And Innovative Companies

• 31.1. Intas Pharmaceuticals Ltd
• 31.2. Aurobindo Pharma
• 31.3. Dr. Reddy's Laboratories
• 31.4. Cipla Limited
• 31.5. Apotex Inc
• 31.6. Zydus Lifesciences Limited
• 31.7. Alvogen
• 31.8. Lotus Pharmaceutical
• 31.9. Natco Pharma Limited
• 31.10. Accord Healthcare
• 31.11. Veranova
• 31.12. Avra Laboratories Pvt. Ltd.
• 31.13. Camber Pharmaceuticals Inc.
• 31.14. Rochem International Inc
• 31.15. Florencia Healthcare

32. Global Lenalidomide Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Lenalidomide Market

34. Recent Developments In The Lenalidomide Market

35. Lenalidomide Market High Potential Countries, Segments and Strategies

• 35.1 Lenalidomide Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Lenalidomide Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Lenalidomide Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer